Phase I trial of OMS 824 binding activity to PDE 10 in brains of healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2014
At a glance
- Drugs OMS 824 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Pharmacodynamics
- 01 Apr 2014 Early findings will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
- 11 Feb 2014 Since the maximum tolerated dose has not been reached in the latest cohort, Omeros is now planning to evaluate a higher dose of OMS 824 in the trial to determine whether a higher level of PDE10 occupancy can be achieved, according to a media release.
- 11 Feb 2014 Additional positive results published in an Omeros Corporation media release.